Abad A, Martínez Balibrea E, Viéitez JM, Alonso Orduña V, García Alfonso P, Manzano JL, et al. Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial. Ann Oncol. 2018;29(2):439-44 [PubMed]

Agud Fernández M, López López F, Díaz Pedroche C, Gómez Martín C. Concurrent inflammatory bowel disease and gastrointestinal stromal tumor. Gastroenterol Hepatol. 2018;41(5):310-1.

Alonso N, Cañueto J, Ciria S, Bueno E, Palacios Álvarez I, Alegre M, et al. Novel clinical and molecular findings in Spanish patients with naevoid basal cell carcinoma syndrome. Br J Dermatol. 2018;178(1):198-206 [PubMed]

Alsina M, Rivera F, Ramos FJ, Galán M, López R, García Alfonso P, et al. A phase II study evaluating combined neoadjuvant cetuximab and chemotherapy followed by chemoradiotherapy and concomitant cetuximab in locoregional oesophageal cancer patients. Target Oncol. 2018;13(1):69-78 [PubMed]

Alsina M, Rivera F, Ramos FJ, Galán M, López R, García Alfonso P, et al. Correction to: A phase II study evaluating combined neoadjuvant cetuximab and chemotherapy followed by chemoradiotherapy and concomitant cetuximab in locoregional oesophageal cancer patients. Target Oncol. 2018;13(1):79 [PubMed]

Álvarez R, Carrato A, Adeva J, Alés I, Prados S, Valladares M, et al. Management of hyperbilirubinaemia in pancreatic cancer patients. Eur J Cancer. 2018;94:26–36 [PubMed]

Angelergues A, Efstathiou E, Gyftaki R, Wysocki PJ, Lainez N, González I, et al. Results of the FLAC European Database of metastatic castration-resistant prostate cancer patients treated with docetaxel, cabazitaxel, and androgen receptor-targeted agents. Clin Genitourin Cancer. 2018;16(4):e777-e784 [PubMed]

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018 13;379(24):2342-50

Aranda E, García Alfonso P, Benavides M, Sánchez Ruiz A, Guillén Ponce C, Safont MJ, et al. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study. Eur J Cancer. 2018;101:263-72.

Arriola E, García Gómez R, Diz P, Majem M, Martínez Aguillo M, Valdivia J, et al. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. BMC Cancer. 2018;18(1):106 [PubMed]

Balañá C, Alonso M, Hernández A, Pérez Segura P, Pineda E, Ramos A, et al. SEOM clinical guidelines for anaplastic gliomas (2017). Clin Transl Oncol. 2018;20(1):16-21 [PubMed]

Balaña C, Estival A, Teruel I, Hardy-Werbin M, Sepúlveda J, Pineda E, et al. Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients. Clin Transl Oncol. 2018;20(12):1529-37 [PubMed]

Barriuso J, Custodio A, Afonso R, Alonso V, Astudillo A, Capdevila J, et al. Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours. Cancer Treat Rev. 2018;70:209-22

Blancas I, Fontanillas M, Conde V, Lao J, Martínez E, Sotelo MJ, et al. Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice. Clin Transl Oncol. 2018;20(7):862-9

Blancas I, Fontanillas M, Conde V, Lao J, Martínez E, Sotelo MJ, et al. Correction to: Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice. Clin Transl Oncol. 2018;20(12):1631-2

Block MS, Vierkant RA, Rambau PF, Winham SJ, Wagner P, Traficante N, et al. MyD88 and TLR4 expression in epithelial ovarian cancer. Mayo Clin Proc. 2018;93(3):307-20 [PubMed]

Bonomi PD, Gandara D, Hirsch FR, Kerr KM, Obasaju C, Paz-Ares L, et al. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. Ann Oncol. 2018;29(8):1701-9

Cala MP, Agulló Ortuño MT, Prieto García E, González Riano C, Parrilla Rubio L, Barbas C, et al. Multiplatform plasma fingerprinting in cancer cachexia: a pilot observational and translational study. J Cachexia Sarcopenia Muscle. 2018;9(2):348–57 [PubMed]

Cantero D, Rodríguez de Lope A, Moreno de la Presa R, Sepúlveda JM, Borrás JM, Castresana JS, et al. Molecular study of long-term survivors of glioblastoma by gene-targeted next-generation sequencing. J Neuropathol Exp Neurol. 2018;77(8):710-6

Carles J, Castellano D, Méndez Vidal MJ, Mellado B, Sáez M-I, González del Alba A, et al. Circulating tumor cells as a biomarker of survival and response to radium-223 therapy: experience in a cohort of patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2018;16(6):e1133-9.

Carles J, Méndez MJ, Pinto A, Sáez MI, Arranz JA, Maroto P, et al. Radium-223 international early access program: results from the Spanish subset. Future Oncol. 2018;14(1):41–50 [PubMed]

Carmona Bayonas A, Jiménez Fonseca P, Custodio A, Sánchez Cánovas M, Hernández R, Pericay C, et al. Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry. Gastric Cancer. 2018;21(1):96–105 [PubMed]

Carmona Bayonas A, Jiménez Fonseca P, Echavarría I, Sánchez Cánovas M, Aguado G, Gallego J, et al. Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry. Eur J Surg Oncol. 2018;44(8):1191-8 [PubMed]

Carretero González A, Lora D, Ghanem I, Zugazagoitia J, Castellano D, Sepúlveda JM, et al. Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials. Oncotarget. 2018;9(9):8706–15 [PubMed]

Carretero González A, Otero I, Carril Ajuria L, De Velasco G, Manso L. Exosomes: Definition, role in tumor development and clinical implications. Cancer Microenviron.
2018;11(1):13-21 [PubMed]

Carril Ajuria L, Jiménez Aguilar E, Gómez Martín C, Díaz Pedroche C. An unsuspected complication with immune checkpoint blockade: a case report. J Med Case Rep. 2018;12(1):246

Castellano D, Maroto JP, Espinosa E, Grande E, Bolós MV, Llinares J, et al. Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies. Expert Opin Drug Saf. 2018;17(6):573-9

Ciruelos E, Vidal M, Martínez de Dueñas E, Martínez Jáñez N, Fernández Y, García Sáenz JA, et al. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain. Clin Transl Oncol. 2018;20(6):753-60

Ciuleanu T, Socinski MA, Obasaju C, Luft AV, Szczesna A, Szafrański W, et al. Efficacy and Safety of necitumumab continuation therapy in the phase III SQUIRE study of patients with stage IV squamous non-small-cell lung cancer. Clin Lung Cancer. 2018;19(2):130–8.e2 [PubMed]

Colomer R, Aranda López I, Albanell J, García Caballero T, Ciruelos E, López García MA, et al. Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol. 2018;20(7):815-26

Colomer R, Aranda López I, Albanell J, García Caballero T, Ciruelos E, López García MÁ, et al. Correction to: Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol. 2018;20(8):1093-5

Conde E, Caminoa A, Domínguez C, Calles A, Walter S, Angulo B, et al. Aligning digital CD8+ scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma. Histopathology. 2018;72(2):270–84 [PubMed]

De Velasco G, Wankowicz SA, Madison R, Ali SM, Norton C, Duquette A, et al. Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. Br J Cancer. 2018;118(9):1238-42 [PubMed]

Díaz Serrano A, Angulo B, Domínguez C, Pazo Cid R, Salud A, Jiménez Fonseca P, et al. Genomic profiling of HER2-positive gastric cancer: PI3K/Akt/mTOR pathway as predictor of outcomes in HER2-positive advanced gastric cancer treated with trastuzumab. Oncologist. 2018;23(9):1092-102 [PubMed]

Díaz Serrano A, Gella P, Jiménez E, Zugazagoitia J, Paz-Ares Rodríguez L. Targeting EGFR in lung cancer: Current standards and developments. Drugs. 2018;78(9):893-911

Di Leo A, Johnston S, Lee KS, Ciruelos E, Lønning PE, Janni W, et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(1):87-100 [PubMed]

Dubsky P, Curigliano G, Burstein HJ, Winer EP, Gnant M, Loibl S, et al. Reply to “The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology” by Kirova et al. Ann Oncol. 2018 1;29(1):281–2 [PubMed]

Escudier B, Powles T, Motzer RJ, Olencki T, Arén Frontera O, Oudard S, et al. Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup Analysis of the METEOR Trial. J Clin Oncol. 2018;36(8):765–72 [PubMed]

Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2017;72:962-71]. Eur Urol. 2018;73(4):e116–8 [PubMed]

Fehrenbacher L, von Pawel J, Park K, Rittmeyer A, Gandara DR, Ponce Aix S, et al. Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab vs docetaxel in patients with previously treated advanced non-small cell lung cancer. J Thorac Oncol. 2018;13(8):1156-70 [PubMed]

Fernández A, Salgado M, García A, Buxò E, Vera R, Adeva J, et al. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study. BMC Cancer. 2018;18(1):1185

Ferrer I, Quintanal Villalonga Á, Molina Pinelo S, García Heredia JM, Pérez M, Suárez R, et al. MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma. J Exp Clin Cancer Res. 2018;37(1):195.

Ferrer I, Zugazagoitia J, Herbertz S, John W, Paz-Ares L, Schmid-Bindert G. KRAS-Mutant non-small cell lung cancer: From biology to therapy. Lung Cancer. 2018;124:53-64

Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018;81:45-51

Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, et al. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018;379(2):122-37

Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, et al. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018;379(2):122-37

Gallardo E, Méndez Vidal MJ, Pérez Gracia JL, Sepúlveda Sánchez JM, Campayo M, Chirivella González I, et al. SEOM clinical guideline for treatment of kidney cancer (2017). Clin Transl Oncol. 2018;20(1):47–56 [PubMed]

Gandara DR, von Pawel J, Mazieres J, Sullivan R, Helland Å, Han JY, et al. Atezolizumab treatment beyond progression in advanced non-small cell lung cancer: Results from the randomized, phase III OAK study. J Thorac Oncol. 2018;13(12):1906-18

Garrido ML, Morago AJ, Rovira PS, Olarte PE, Sánchez CP, Sánchez LM. Experience with eribulin in the treatment of elderly women with metastatic breast cancer: case studies. Future Oncol. 2018;14(7s):21–7 [PubMed]

Giaccone G, Sanborn RE, Waqar SN, Martínez Marti A, Ponce S, Zhen H, et al. A placebo-controlled phase II study of ruxolitinib in combination with pemetrexed and cisplatin for first-line treatment of patients with advanced nonsquamous non-small-cell lung cancer and systemic inflammation. Clin Lung Cancer. 2018;19(5):e567-e574 [PubMed]

Gillessen S, Attard G, Beer TM, Beltrán H, Bossi A, Bristow R, et al. Management of patients with advanced prostate cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018;73(2):178–211 [PubMed]

Gillison ML, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. CheckMate 141: 1-year update and subgroup analysis of nivolumab as first-line therapy in patients with recurrent/Metastatic head and neck cancer. Oncologist. 2018;23(9):1079-82

Grávalos C, Carrato A, Tobeña M, Rodríguez Garrote M, Soler G, Vieítez JM, et al. A randomized phase II study of axitinib as maintenance therapy after first-line treatment for metastatic colorectal cancer. Clin Colorectal Cancer. 2018;17(2):e323-e329 [PubMed]

Gridelli C, Baas P, Barlesi F, Ciardiello F, Crinò L, Felip E, et al. Second-line treatment options in non-small-cell lung cancer: report from an International Experts Panel meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer. 2018;19(4):301-14.

Guerrero Ramos F, Castellano Gauna D, García Rojo E, Duarte Ojeda JM, De la Rosa Kehrmann F, Villacampa Aubá F. HIVEC con mitomicina C. Actualización y resultados en pacientes de alto riesgo. Arch Esp Urol. 2018;71(4):417–25 [PubMed]

Harshman LC, Xie W, Moreira RB, Bossé D, Ruiz Ares GJ, Sweeney CJ, et al. Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis. Cancer. 2018;124(5):925–33 [PubMed]

Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier Valette C, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018 31;378(22):2093–104 [PubMed]

Hellmann MD, Paz-Ares L. Lung cancer with a high tumor mutational burden. N Engl J Med. 2018;379(11):1093-4.

Herrera M, Llorens C, Rodríguez M, Herrera A, Ramos R, Gil B, et al. Differential distribution and enrichment of non-coding RNAs in exosomes from normal and Cancer-associated fibroblasts in colorectal cancer. Mol Cancer. 2018;17(1):114.

Hirsch FR, Kerr KM, Bunn PA, Kim ES, Obasaju C, Pérol M, et al. Molecular and immune biomarker testing in squamous-cell lung cancer: Effect of current and future therapies and technologies. Clin Lung Cancer. 2018;19(4):331-9 [PubMed]

Iglesias Docampo LC, Arrazubi Arrula V, Baste Rotllan N, Carral Maseda A, Cirauqui Cirauqui B, Escobar Y, et al. SEOM clinical guidelines for the treatment of head and neck cancer (2017). Clin Transl Oncol. 2018;20(1):75–83 [PubMed]

Jara C, Del Barco S, Grávalos C, Hoyos S, Hernández B, Muñoz M, et al. SEOM clinical guideline for treatment of cancer pain (2017). Clin Transl Oncol. 2018;20(1):97–107 [PubMed]

Jiménez Aguilar E, Zugazagoitia Fraile J, Paz-Ares Rodríguez L. Necitumumab: a new option for first-line treatment of squamous cell lung cancer. Expert Opin Drug Metab Toxicol. 2018;14(8):765-72

Kim ES, Kelly K, Paz-Ares LG, Garrido P, Jalal S, Mahadevan D, et al. Abemaciclib in combination with single-agent options in patients with stage iv non-small cell lung cancer: a phase ib study. Clin Cancer Res. 2018;24(22):5543-51

Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, et al. A pan-cancer analysis reveals high-frequency genetic alterations in mediators of signaling by the TGF-β superfamily. Cell Syst. 2018;7(4):422-437.e7

Krauss T, Ferrara AM, Links TP, Wellner U, Bancos I, Kvachenyuk A, et al. Preventive medicine for von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors. Endocrine-Related Cancer. 2018;25(9):783-93 [PubMed]

Liu X, Swen JJ, Diekstra MHM, Boven E, Castellano D, Gelderblom H, et al. A genetic polymorphism in CTLA-4 is associated with overall survival in sunitinib-treated patients with clear cell metastatic renal cell carcinoma. Clin Cancer Res. 2018;24(10):2350-6 [PubMed]

López Valero I, Sáiz Ladera C, Torres S, Hernández Tiedra S, García Taboada E, Rodríguez Fornés F, et al. Targeting glioma initiating cells with a combined therapy of cannabinoids and temozolomide. Biochem Pharmacol. 2018;157:266-74

López Valero I, Torres S, Salazar Roa M, García Taboada E, Hernández Tiedra S, Guzmán M, et al. Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma. Biochem Pharmacol. 2018;157:275-84.

Losa F, Iglesias L, Pané M, Sanz J, Nieto B, Fusté V, et al. 2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary. Clin Transl Oncol. 2018;20(11):1361-72

Manso L, Sánchez Muñoz A, Calvo I, Izarzugaza Y, Plata J, Rodríguez C. Late administration of trastuzumab emtansine might lead to loss of chance for better outcome in patients with HER2-positive ,etastatic breast cancer. Breast Care (Basel). 2018;13(4):277-83

Marrugal A, Ojeda L, Paz Ares L, Molina Pinelo S, Ferrer I. Corrigendum to “Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer.” Dis Markers. 2018;2018:1404780.

Martín Liberal J, López Pousa A, Martínez Trufero J, Martín Broto J, Cubedo R, Lavernia J, et al. Phase II study of gemcitabine plus sirolimus in previously treated patients with advanced soft-tissue sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study. Target Oncol. 2018;13(1):81-7 [PubMed]

Martínez Pérez J, Riesco Martínez MC, García Carbonero R. The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer. Expert Opìn Drug Saf. 2018;17(6):643-50 [PubMed]

McKay RR, Bossé D, Xie W, Wankowicz SAM, Flaifel A, Brandao R, et al. The clinical activity of PD-1/PD-L1 inhibitors in metastatic non-clear cell renal cell carcinoma. Cancer Immunol Res. 2018;6(7):758-65 [PubMed]

Melisi D, García Carbonero R, Macarulla T, Pezet D, Deplanque G, Fuchs M, et al. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. Br J Cancer. 2018;119(10):1208-14

Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol. 2018;4(3):351–7 [PubMed]

Middleton G, Gridelli C, De Marinis F, Pujol JL, Reck M, Ramlau R, et al. Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Curr Med Res Opin. 2018;34(5):865–71 [PubMed]

Molina Pinelo S, Salinas A, Moreno Mata N, Ferrer I, Suárez R, Andrés León E, et al. Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer. Oncotarget. 2018;9(4):4395-410 [PubMed]

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–90 [PubMed]

Muñoz Unceta N, Burgueño I, Jiménez E, Paz-Ares L. Durvalumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2018;10:1758835918804151.

Mytelka DS, Nagar SP, D’yachkova Y, La EM, Kaye JA, Candrilli SD, et al. Health care resource utilization and costs among adult patients with advanced soft tissue sarcoma: A retrospective medical record review in the United Kingdom, Spain, Germany, and France. Sarcoma. 2018;2018:2020591

Nagar SP, Mytelka DS, Candrilli SD, D’yachkova Y, Lorenzo M, Kasper B, et al. Treatment patterns and survival among adult patients with advanced soft tissue sarcoma: A retrospective medical record review in the United Kingdom, Spain, Germany, and France. Sarcoma. 2018;2018:5467057

Nuciforo P, Pascual T, Cortés J, Llombart-Cussac A, Fasani R, Paré L, et al. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. Ann Oncol. 2018;29(1):170–7 [PubMed]

Núñez Valdovinos B, Carmona Bayonas A, Jiménez Fonseca P, Capdevila J, Castaño Pascual A, Benavent M, et al. Neuroendocrine tumor heterogeneity adds uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE). Oncologist. 2018;23(4):422–32 [PubMed]

Oskay Özcelik G, Alavi S, Richter R, Keller M, Chekerov R, Cecere SC, et al. Expression III: patients’ expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries. Ann Oncol. 2018;29(4):910–6 [PubMed]

Palacios Calvo J, Albanell J, Rojo F, Ciruelos E, Aranda López I, Cortés J, et al. Consenso de la Sociedad Española de Anatomía Patológica y la Sociedad Española de Oncología Médica sobre biomarcadores en cáncer de mama]. Rev Esp Patol. 2018;51(2):97–109 [PubMed]

Patel JD, Paz-Ares L, Zinner RG, Barlesi F, Koustenis AG, Obasaju CK. Pemetrexed continuation maintenance phase 3 trials in nonsquamous, non-small-cell lung cancer: focus on 2-year overall survival and continuum of care. Clin Lung Cancer. 2018;19(6):e823-30

Pavel M, Gross DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, et al. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. Endocr Relat Cancer. 2018;25(3):309–22 [PubMed]

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 22;379(21):2040-51

Pena Couso L, Perea J, Melo S, Mercadillo F, Figueiredo J, Sanches JM, et al. Clinical and functional characterization of the CDH1 germline variant c.1679C>G in three unrelated families with hereditary diffuse gastric cancer. Eur J Hum Genet. 2018;26(9):1348-53 [PubMed]

Pernas S, Martín M, Kaufman PA, Gil Martín M, Gómez Pardo P, López Tarruella S, et al. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. Lancet Oncol. 2018;19(6):812-24 [PubMed]

Pernaut C, López F, Ciruelos E. Standard neoadjuvant treatment in early/locally advanced breast cancer. Breast Care (Basel). 2018;13(4):244-9

Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748–57 [PubMed]

Quintanal Villalonga A, Mediano M, Ferrer I, Meléndez R, Carranza Carranza A, Suárez R, et al. Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer. Oncotarget. 2018;9(28):19945–60 [PubMed]

Quintanal Villalonga A, Ojeda Márquez L, Marrugal A, Yagüe P, Ponce Aix S, Salinas A, et al. The FGFR4-388arg variant promotes lung cancer progression by N-cadherin induction. Sci Rep. 2018;8(1):2394 [PubMed]

Quintanal Villalonga A, Paz Ares L, Ferrer I, Molina Pinelo S. Corrigendum to “Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications.” Dis Markers. 2018;2018:3714684.

Reck M, Garon EB, Paz-Ares L, Ponce S, Jaime JC, Juan O, et al. Randomized, double-blind phase Ib/III study of erlotinib with ramucirumab or placebo in previously untreated EGFR-mutant metastatic non-small-cell lung cancer (RELAY): Phase Ib results. Clin Lung Cancer. 2018;19(3):213–20.e4 [PubMed]

Redondo A, Ramos Vázquez M, Manso L, Gil Gil MJ, Garau Llinas I, García-Garre E, et al. Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational “LORENA” study. Onco Targets Ther. 2018;11:5845-52

Salazar R, García Carbonero R, Libutti SK, Hendifar AE, Custodio A, Guimbaud R, et al. Phase II study of BEZ235 versus everolimus in patients with mammalian target of rapamycin inhibitor-naïve advanced pancreatic neuroendocrine tumors. Oncologist. 2018;23(7):766-e90

Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747-757 [PubMed]

Schneeweiss A, Park-Simon T-W, Albanell J, Lassen U, Cortés J, Dieras V, et al. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. Invest New Drugs. 2018;36(5):848-59 [PubMed]

Segrelles C, Contreras D, Navarro EM, Gutiérrez Muñoz C, García Escudero R, Paramio JM, et al. Bosutinib inhibits EGFR activation in head and neck cancer. Int J Mol Sci. 2018;19(7)

Sepúlveda JM, Sánchez Gómez P, Vaz Salgado MÁ, Gargini R, Balañá C. Dacomitinib: an investigational drug for the treatment of glioblastoma. Expert Opin Investig Drugs. 2018;27(10):823-9

Sepúlveda Sánchez JM, Muñoz Langa J, Arráez MA, Fuster J, Hernández Laín A, Reynés G, et al. SEOM clinical guideline of diagnosis and management of low-grade glioma (2017). Clin Transl Oncol. 2018;20(1):3–15 [PubMed]

Sepúlveda Sánchez JM, Muñoz Langa J, Arráez MA, Fuster J, Hernández Laín A, Reynés G, et al. Correction to: SEOM clinical guideline of diagnosis and management of low-grade glioma (2017). Clin Transl Oncol. 2018;20(1):108–9 [PubMed]

Siena S, Sartore Bianchi A, García Carbonero R, Karthaus M, Smith D, Tabernero J, et al. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. Ann Oncol. 2018;29(1):119–26 [PubMed]

Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn PA, et al. Current and emergent therapy options for advanced squamous cell lung cancer. J Thorac Oncol. 2018;13(2):165–83 [PubMed]

Tabernero J, Hozak RR, Yoshino T, Cohn AL, Obermannova R, Bodoky G, et al. Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study. Ann Oncol. 2018;29(3):602–9 [PubMed]

Thomas M, Ponce Aix S, Navarro A, Riera Knorrenschild J, Schmidt M, Wiegert E, et al. Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study. Ann Oncol. 2018;29(10):2076-84.

Van Cutsem E, Mayer RJ, Laurent S, Winkler R, Grávalos C, Benavides M, et al. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur J Cancer. 2018;90:63–72 [PubMed]

Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol. 2018;19(12):1680-7

Vergote I, Von Moos R, Manso L, Van Nieuwenhuysen E, Concin N, Sessa C. Tumor treating fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study. Gynecol Oncol. 2018;150(3):471-7.

Visa L, Jiménez Fonseca P, Martínez EA, Hernández R, Custodio A, Garrido M, et al. Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis. J Geriatr Oncol. 2018;9(3):254-64.

Von Hoff DD, Rasco DW, Heath EI, Munster PN, Schellens JHM, Isambert N, et al. Phase I study of CC-486 alone and in combination with carboplatin or nab‑paclitaxel in patients with relapsed or refractory solid tumors. Clin Cancer Res. 2018;24(17):4072-80 [PubMed]

Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29(suppl_1):i10–9

Wu YL, Sequist LV, Tan EH, Geater SL, Orlov S, Zhang L, et al. Afatinib as first-line treatment of older patients with EGFR mutation-positive non-small-cell lung cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. Clin Lung Cancer. 2018;19(4):e465-e479 [PubMed]

Young K, Paz-Ares L, Thatcher N, Spigel DR, Shahidi J, Soldatenkova V, et al. Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis. Thromb Res. 2018;167:50-6

Zagorac I, Fernández Gaitero S, Penning R, Post H, Bueno MJ, Mouron S, et al. In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer. Nat Commun. 2018;9(1):3501

Zugazagoitia J, Biosca M, Olivera J, Eugenia Olmedo M, Dómine M, Nadal E, et al. Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small-cell lung cancer. Eur Respir J. 2018;51(5) [PubMed]

Zugazagoitia J, Rueda D, Carrizo N, Enguita AB, Gómez Sánchez D, Díaz Serrano A, et al. Prospective clinical integration of an amplicon-based next-generation sequencing method to select advanced non-small-cell lung cancer patients for genotype-tailored treatments. Clin Lung Cancer. 2018;19(1):65–73.e7 [PubMed]